MDWD Valuation

Mediwound Ltd

Add to Watchlist

Advanced Chart

16.840

-0.41(-2.377%)1D

Overview
Forecast
Valuation
Earnings

MDWD Relative Valuation

MDWD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MDWD is overvalued; if below, it's undervalued.

Historical Valuation

Mediwound Ltd (MDWD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.87 is considered Undervalued compared with the five-year average of -9.31. The fair price of Mediwound Ltd (MDWD) is between 19.74 to 27.18 according to relative valuation methord. Compared to the current price of 16.89 USD , Mediwound Ltd is Undervalued By 14.46%.

Relative Value

Fair Zone

19.74-27.18

Current Price：16.89

14.46%

Undervalued

-6.33

Trailing

Forward

-5.14

EV/EBITDA

Mediwound Ltd. (MDWD) has a current EV/EBITDA of -5.14. The 5-year average EV/EBITDA is -4.78. The thresholds are as follows: Strongly Undervalued below -18.28, Undervalued between -18.28 and -11.53, Fairly Valued between 1.97 and -11.53, Overvalued between 1.97 and 8.72, and Strongly Overvalued above 8.72. The current Forward EV/EBITDA of -5.14 falls within the Historic Trend Line -Fairly Valued range.

-5.77

EV/EBIT

Mediwound Ltd. (MDWD) has a current EV/EBIT of -5.77. The 5-year average EV/EBIT is -7.18. The thresholds are as follows: Strongly Undervalued below -20.96, Undervalued between -20.96 and -14.07, Fairly Valued between -0.29 and -14.07, Overvalued between -0.29 and 6.60, and Strongly Overvalued above 6.60. The current Forward EV/EBIT of -5.77 falls within the Historic Trend Line -Fairly Valued range.

6.87

Mediwound Ltd. (MDWD) has a current PS of 6.87. The 5-year average PS is 5.02. The thresholds are as follows: Strongly Undervalued below 1.24, Undervalued between 1.24 and 3.13, Fairly Valued between 6.91 and 3.13, Overvalued between 6.91 and 8.80, and Strongly Overvalued above 8.80. The current Forward PS of 6.87 falls within the Historic Trend Line -Fairly Valued range.

-7.25

P/OCF

Mediwound Ltd. (MDWD) has a current P/OCF of -7.25. The 5-year average P/OCF is -7.59. The thresholds are as follows: Strongly Undervalued below -27.31, Undervalued between -27.31 and -17.45, Fairly Valued between 2.27 and -17.45, Overvalued between 2.27 and 12.14, and Strongly Overvalued above 12.14. The current Forward P/OCF of -7.25 falls within the Historic Trend Line -Fairly Valued range.

-6.51

P/FCF

Mediwound Ltd. (MDWD) has a current P/FCF of -6.51. The 5-year average P/FCF is -3.15. The thresholds are as follows: Strongly Undervalued below -12.15, Undervalued between -12.15 and -7.65, Fairly Valued between 1.35 and -7.65, Overvalued between 1.35 and 5.84, and Strongly Overvalued above 5.84. The current Forward P/FCF of -6.51 falls within the Historic Trend Line -Fairly Valued range.

Mediwound Ltd (MDWD) has a current Price-to-Book (P/B) ratio of 9.52. Compared to its 3-year average P/B ratio of 7.37 , the current P/B ratio is approximately 29.20% higher. Relative to its 5-year average P/B ratio of 4.84, the current P/B ratio is about 96.69% higher. Mediwound Ltd (MDWD) has a Forward Free Cash Flow (FCF) yield of approximately -10.06%. Compared to its 3-year average FCF yield of -13.61%, the current FCF yield is approximately -26.09% lower. Relative to its 5-year average FCF yield of -12.77% , the current FCF yield is about -21.20% lower.

9.32

P/B

Median3y

7.37

Median5y

4.84

-10.06

FCF Yield

Median3y

-13.61

Median5y

-12.77

Competitors Valuation Multiple

The average P/S ratio for MDWD's competitors is 24.01, providing a benchmark for relative valuation. Mediwound Ltd Corp (MDWD) exhibits a P/S ratio of 6.87, which is -71.39% above the industry average. Given its robust revenue growth of 12.74%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Enanta Pharmaceuticals Inc

RAPT Therapeutics Inc

Loss

186.63M

ACRS.O

Aclaris Therapeutics Inc

29.69

-35.76%

196.08M

Performance Decomposition

Market capitalization of MDWD decreased by 8.43% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -124.53 to -233.32.

The secondary factor is the Revenue Growth, contributed 12.74%to the performance.

Overall, the performance of MDWD in the past 1 year is driven by Margin Expansion. Which is more sustainable.

12.74%

5.06M → 5.71M

Revenue Growth

87.36%

-124.53 → -233.32

Margin Expansion

-108.53%

76.92 → -6.56

P/E Change

-8.43%